Supply High quality Prasugrel powder //CAS: 150322-43-3 CAS NO.150322-43-3

FOB Price:: USD 1.00-1.00 /Metric Ton Get Latest Price

Min.Order Quantity:: 1 Metric Ton

Purity:: 99%min

Port:: Shanghai port

Payment Terms:: L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

Supply High quality Prasugrel powder //CAS: 150322-43-3
Prasugrel powder
CAS 150322-43-3

Quick Details

ProName: Supply High quality Prasugrel powder /...
CasNo: 150322-43-3
Molecular Formula: C20H20FNO3S
Appearance: WhitePowder
Application: pharmaceutical intermediates
DeliveryTime: within 5-7 days after payment
PackAge: 25kg/ drum, or as your requirements
Port: Shanghai port
ProductionCapacity: 100 Metric Ton/Month
Purity: 99%min
Storage: regualr storage
Transportation: By air、ship and courier
LimitNum: 1 Metric Ton
Related Substances: undetected
Residue on Ignition: less than 0.05%
Heavy Metal: less than 0.02%
Valid Period: 3 years
EINECS: 200-659-6
Application: Pharm Intermediates
Appearance: WhitePowder
Molecular Weig: 373.44
Melting point: 184°C
Brand: zhishang
Product name: Prasugrel
HPLC: available
NMR: available

Superiority

1.professional manufacturer

2.best price

3.fast delivery

4.prompt before and after sale service

5.quality guarantee

6.reliable and truthworthy supplier

Details

supply high quality prasugrel powder //cas: 150322-43-3

prasugrel intermediate

1.prasugrel hcl

2.used as cardiovascular drug

3.supplly with competitive price

prasugrel medicine grade

items	specifications	results
appearance	white powder	white powder
assay( on dried, hplc)	≥99.0%	99.3%
related substance	conforms	conforms
heavy metal( as pb)	≤0.002%	<0.002%
loss on drying	≤0.2%	conforms

prasugrel is a novel platelet inhibitor developed by daiichi sankyo co. and produced by ube and currently marketed in the united states in cooperation with eli lilly and company for acute coronary syndromes planned for percutaneous coronary intervention (pci). prasugrel was approved for use in europe in february 2009, and is currently available in the uk. on july 10, 2009, the us food and drug administration approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with pci